Pfizer
Prescription medicines, vaccines and consumer products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | €3.3b | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 94 % | 23 % | (42 %) | 9 % | (2 %) | - | (2 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 35 % | 43 % | 25 % | 37 % | 40 % | 42 % | 43 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 27 % | 31 % | 4 % | 13 % | 19 % | 22 % | 22 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 17 % | 11 % | 18 % | 17 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Pfizer Inc. is a leading biopharmaceutical company that focuses on the discovery, development, and manufacture of healthcare products. Operating in the global healthcare market, Pfizer serves a diverse range of clients including governments, healthcare providers, and patients. The company’s business model revolves around the research and development of innovative medicines and vaccines, which are then commercialized and distributed worldwide. Pfizer generates revenue through the sale of its pharmaceutical products, which include vaccines, oncology treatments, and other specialized medicines. The company has been at the forefront of the fight against COVID-19, partnering with BioNTech to develop and distribute a highly effective vaccine. Pfizer's commitment to public health is further demonstrated by its initiatives to provide vaccines to underserved populations. The company continues to expand its portfolio with new approvals and authorizations for various treatments, ensuring a steady pipeline of future products.
Keywords: biopharmaceutical, vaccines, oncology, healthcare, global market, innovation, COVID-19, BioNTech, public health, research and development.
Tech stack
